Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2015 | Original Article – Clinical Oncology

Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis

Authors: Shuangnian Xu, Xi Li, Jianmin Zhang, Jieping Chen

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2015

Abstract

Purpose

Extensive studies have investigated the prognostic value of CD56 for patients with acute myeloid leukemia (AML), but the results remained inconclusive. The aim of this meta-analysis is to resolve this controversial issue.

Methods

A systematic search of PubMed, Embase, Cochrane Library, and CBM was performed to identify studies that assessed the prognostic value of CD56 in AML patients. Pooled hazard ratios (HRs) with 95 % confidence intervals (CIs) for overall survival (OS) and disease-free survival (DFS) and pooled odds ratio (OR) with 95 % CIs for complete remission rate (CRR) and relapse rate (RR) were calculated.

Results

Totally, 32 studies with 4074 patients were included. For AML with t(8;21) translocation, CD56 overexpression was associated with shorter OS (HR 2.22; 95 % CI 1.30–3.78) and DFS (HR 2.63; 95 % CI 1.10–6.29) and increased RR (OR 3.29; 95 % CI 1.67–6.48), but did not affect CRR (OR 0.94; 95 % CI 0.49–1.80). For AML with t(15;17) translocation, CD56 overexpression was associated with shorter OS (HR 2.43; 95 % CI 1.66–3.57) and DFS (HR 4.27; 95 % CI 1.15–15.78), increased RR (OR 3.11; 95 % CI 2.01–4.81), and decreased CRR (OR 0.42; 95 % CI 0.25–0.72). For AML as a whole, CD56 overexpression was associated with shorter OS (HR 1.74; 95 % CI 1.38–2.19) and DFS (HR 2.38; 95 % CI 1.87–3.02), increased RR (OR 5.19; 95 % CI 2.84–9.48), and decreased CRR (OR 0.62; 95 % CI 0.41–0.96).

Conclusions

This meta-analysis indicated that CD56 overexpression may be an adverse prognostic factor for AML.

Available only for authorised users

Alegretti AP et al (2011) The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia. Revista brasileira de hematologia e hemoterapia 33:202–206. doi:10.5581/1516-8484.20110054 PubMedCentralCrossRefPubMed

Baer MR et al (1997) Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). Blood 90:1643–1648PubMed

Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50:1088–1101CrossRefPubMed

Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33:451–458CrossRefPubMed

Bochtler T et al (2013) Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol 31:3898–3905. doi:10.1200/jco.2013.50.7921 CrossRefPubMed

Breccia M et al (2014) Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients. Leuk Res 38:194–197. doi:10.1016/j.leukres.2013.11.008 CrossRefPubMed

Chang H, Salma F, Yi QL, Patterson B, Brien B, Minden MD (2004) Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res 28:43–48CrossRefPubMed

Chaudhri NA et al (2011) Expression of CD56 in acute myeloid leukemia (AML) is associated with poor outcome when patients treated with stem cell transplant in second remission but not in the first remission. Blood 118:2011–2012

Chen G, Jia H, Bian S, Shen D, Han M, Zhang J (1997) Clinical and MIC characteristics of CD56 positive acute non-lymphoblastic leukemia. Leuk Lymphoma 36:480–482

Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury R, Edelman GM (1987) Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science (New York, NY) 236:799–806CrossRef

Dang H, Jiang A, Kamel-Reid S, Brandwein J, Chang H (2013) Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum Pathol 44:55–61. doi:10.1016/j.humpath.2012.04.008 CrossRefPubMed

Di Bona E, Sartori R, Zambello R, Guercini N, Madeo D, Rodeghiero F (2002) Prognostic significance of CD56 antigen expression in acute myeloid leukemia. Haematologica 87:250–256PubMed

Djunic I et al (2012) Prognostic significance of CD56 antigen expression in patients with acute myeloid leukemia. Med Oncol 29:2077–2082. doi:10.1007/s12032-011-0104-9 CrossRefPubMed

Drach D, Zhao S, Drach J, Mahadevia R, Gattringer C, Huber H, Andreeff M (1992) Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 80:2729–2734PubMed

Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed) 315:629–634CrossRef

Ferrara F, Schiffer CA (2013) Acute myeloid leukaemia in adults. Lancet 381:484–495. doi:10.1016/s0140-6736(12)61727-9 CrossRefPubMed

Ferrara F et al (2000) CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy. J Clin Oncol 18:1295–1300PubMed

Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clin Res ed) 327:557–560. doi:10.1136/bmj.327.7414.557 CrossRef

Hildreth CJ, Lynm C, Glass RM (2010) Acute myeloid leukemia. JAMA 304:2759. doi:10.1001/jama.302.22.2759 CrossRefPubMed

Hsiao CH et al (2002) High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan. J Formos Med Assoc 101:393–398PubMed

Iriyama N et al (2013) CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res 37:1021–1026. doi:10.1016/j.leukres.2013.05.002 CrossRefPubMed

Ito S et al (2004) Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia. Leuk Lymphoma 45:1783–1789. doi:10.1080/10428190410001683624 CrossRefPubMed

Jiang A et al (2011a) Prognostic impact of immunophenotyping in elderly acute myeloid leukemia with normal karyotype. Lab Invest 91(Suppl. 1):303A

Jiang A, Jiang H, Brandwein J, Kamel-Reid S, Chang H (2011b) Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leuk Res 35:492–498. doi:10.1016/j.leukres.2010.07.021 CrossRefPubMed

Junca J et al (2014) Correlation of CD11b and CD56 expression in adult acute myeloid leukemia with cytogenetic risk groups and prognosis. Ann Hematol 93:1483–1489. doi:10.1007/s00277-014-2082-4 CrossRefPubMed

Kohnke T et al (2014) Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse. Leukemia. doi:10.1038/leu.2014.186 PubMed

Lanier LL, Testi R, Bindl J, Phillips JH (1989) Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 169:2233–2238CrossRefPubMed

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMed

Marcucci G et al (2014) Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score. J Clin Oncol 32:548–556. doi:10.1200/jco.2013.50.6337 PubMedCentralCrossRefPubMed

Mason KD, Juneja SK, Szer J (2006) The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis? Blood Rev 20:71–82. doi:10.1016/j.blre.2005.08.002 CrossRefPubMed

Mendler JH et al (2012) RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures. J Clin Oncol 30:3109–3118. doi:10.1200/jco.2011.40.6652 PubMedCentralCrossRefPubMed

Middeke JM et al (2014) Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 123:2960–2967. doi:10.1182/blood-2013-12-544957 CrossRefPubMed

Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097. doi:10.1371/journal.pmed.1000097 PubMedCentralCrossRefPubMed

Montesinos P et al (2011) Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood 117:1799–1805. doi:10.1182/blood-2010-04-277434 CrossRefPubMed

Murray CK et al (1999) CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J Clin Oncol 17:293–297PubMed

Ono T et al (2014) Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts. Cancer Sci 105:97–104. doi:10.1111/cas.12319 CrossRefPubMed

Orendi K, Emberger W, Speicher MR, Hoefler G, Sill H (2013) Molecular cytogenetics and multiplex reverse-transcriptase polymerase chain reaction for risk stratification in acute myeloid leukemia. J Clin Oncol 31:2360–2361. doi:10.1200/jco.2013.48.8189 CrossRefPubMed

Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 17:2815–2834CrossRefPubMed

Pastore F et al (2014) Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia. J Clin Oncol 32:1586–1594. doi:10.1200/jco.2013.52.3480 CrossRefPubMed

Raspadori D et al (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15:1161–1164CrossRefPubMed

Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603–605. doi:10.1007/s10654-010-9491-z CrossRefPubMed

Tan T, Wu M, Chiou L (2011) CD56 positivity is a poor prognostic factor in AML patients undergoing stem cell transplant. Bone Marrow Transplant 46:S281

Thomas X, Vila L, Campos L, Sabido O, Archimbaud E (1995) Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. Leuk Lymphoma 19:295–300. doi:10.3109/10428199509107901 CrossRefPubMed

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16. doi:10.1186/1745-6215-8-16 PubMedCentralCrossRefPubMed

Valgardsdottir R et al (2014) Direct involvement of CD56 in CIK-mediated lysis of CD56 hematopoietic target cells. Exp Hematol 42:1013–1021. doi:10.1016/j.exphem.2014.08.005 CrossRefPubMed

Vardiman JW et al (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951. doi:10.1182/blood-2009-03-209262 CrossRefPubMed

Wang D et al (2005) The biological and clinical significance of CD56+ antigen expression in child acute myeloid leukemia. Chin Pediatr Hematol 10:160–163

Wang D et al (2006) The clinical and biological characteristics of CD56+ elderly acute myeloid leukemia. Chin J Geratol 26:1181–1183

Xiong Y et al (2005) Significance of CD56 antigen expression in acute monocytic leukemia cells. J Clin Hematol 18:334–337

Xu B, Xiao P, Song X, Shi P, Yi Z, Zhou S (2009) Significance of quantification of MDR1 gene and CD56 antigen expression in acute myeloid leukemia patients Chin J. Microbiol Immunol 29:1080–1083

Xue A, Feng A, Zhao P, Zhang H (2013) The correlation of the expression of CD56 antigen to the relapse of acute promyelocytic leukemia. Health Res 33:345–347

Yang DH et al (2007) Predictable prognostic factor of CD56 expression in patients with acute myeloid leukemia with t(8:21) after high dose cytarabine or allogeneic hematopoietic stem cell transplantation. Am J Hematol 82:1–5. doi:10.1002/ajh.20739 CrossRefPubMed

Yang LL, Gan SL, Liu YF, Zhang QT, Li T, Ma J, Sun H (2013) Clinical characteristics of CD56(+) patients with acute monocytic leukemia and their prognostic significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 21:596–600. doi:10.7534/j.issn.1009-2137.2013.03.012 PubMed

Zhang W et al (2001) Clinical significance and hematologic features of CD56+ acute myeloid leukemia. China Oncol 11:488–492

Zhang Y et al (2002) Expression of CD56 in acute leukemia and its clinical significance. Zhongguo Shi Yan Xue Ye Xue Za Zhi 10:187–190PubMed

Zhang L, Ren C, Luo W, Feng C, Guo Q (2007) Expression of c-kit and CD56 in bone marrow monocyte of acute myeloid leukemia patients. Shandong Pharm Med 47:37–38

Title: Prognostic value of CD56 in patients with acute myeloid leukemia: a meta-analysis
Authors: Shuangnian Xu
Xi Li
Jianmin Zhang
Jieping Chen
Publication date: 01-10-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2015
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-015-1977-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2015

Hypoxia-induced nitric oxide release by luminal cells stimulates proliferation and uPA secretion of myoepithelial cells in a bicellular murine mammary tumor

p53 target gene Rap2B regulates the cytoskeleton and inhibits cell spreading

Sensitivity to systemic therapy for metastatic breast cancer in CHEK2 1100delC mutation carriers

Leukocyte telomere length: a novel biomarker to predict the prognosis of glioma patients

Prospective study of the safety and efficacy of a pancreatic cancer stem cell vaccine

Preoperative anemia is associated with adverse outcome in patients with urothelial carcinoma of the bladder following radical cystectomy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials